Monogram Health Closes $375M Growth Capital

Milestone funding from leading strategic and financial investors will help accelerate company's mission to measurably improve outcomes for patients living with polychronic conditions, including chronic kidney and end-stage renal disease

by

Monogram Health, a value-based specialist provider of in-home evidence-based care and benefit management services for patients with polychronic illnesses such as chronic kidney disease and end-stage renal disease, said today that it has closed on $375 million in new capital.

Leading strategic investors CVS Health, Cigna Ventures, Humana, Memorial Hermann Health System, and SCAN participated in this milestone growth funding round, as did new and existing financial investors such as TPG Capital, Frist Cressey Ventures, Heritage Group, Pura Vida Investments, and Norwest Venture Partners.

Access to the type of specialist care that Monogram provides is crucial for the more than 37 million American individuals who have chronic renal disease. The company’s vast market-based teams of clinicians, lead by physicians and nurse practitioners and backed by registered nurses, social workers, pharmacists, and care management teams, drive Monogram’s revolutionary, high-touch, and in-home strategy.

These physicians and clinical expertise are supported even further by utilization management teams that focus on hospitalizations and discharge management, personalizing the experience and care for Monogram patients in roughly 4,000 communities across 34 states.

Monogram’s investor base now serves more than 30% of Medicare Advantage members nationwide and up to 40% of the U.S. population, uniquely enabling the company to serve patients suffering with chronic kidney disease and related metabolic illnesses.

BofA Securities acted as sole placement agent and Cravath, Swaine & Moore LLP served as legal counsel to Monogram in connection with the transaction.

Monogram Health is a leading value-based specialty provider of in-home evidence-based care and benefit management services for patients living with polychronic conditions, including chronic kidney and end-stage renal disease. The company deploys an innovative in-home care delivery model and a technology-driven array of evidence-based clinical services, including complex case and disease management, utilization management, and medication therapy management to transform the way health care is delivered for those with polychronic conditions.

This innovative model of care has been shown to dramatically improve patient outcomes and quality of life while reducing medical costs across the health care continuum. Based in Nashville, Tennessee, and privately held by Frist Cressey Ventures, TPG Capital, Norwest Venture Partners, as well as other leading strategic and financial investors, Monogram Health has numerous value-based partnerships with leading health plans and risk-bearing providers to care for patients across 34 states and all insurance products.

Related Stories

Latest News Stories